Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Expenses: 2010-2025

Historic Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $7.5 million.

  • Lineage Cell Therapeutics' Operating Expenses fell 2.00% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.0 million, marking a year-over-year increase of 47.46%. This contributed to the annual value of $31.0 million for FY2024, which is 8.02% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Operating Expenses of $7.5 million as of Q3 2025, which was down 66.88% from $22.5 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Operating Expenses peaked at $29.2 million during Q4 2021, and registered a low of $7.3 million during Q2 2024.
  • Over the past 3 years, Lineage Cell Therapeutics' median Operating Expenses value was $8.0 million (recorded in 2025), while the average stood at $9.3 million.
  • In the last 5 years, Lineage Cell Therapeutics' Operating Expenses skyrocketed by 376.92% in 2021 and then plummeted by 71.06% in 2022.
  • Lineage Cell Therapeutics' Operating Expenses (Quarterly) stood at $29.2 million in 2021, then tumbled by 71.06% to $8.5 million in 2022, then fell by 3.05% to $8.2 million in 2023, then dropped by 2.64% to $8.0 million in 2024, then decreased by 2.00% to $7.5 million in 2025.
  • Its Operating Expenses stands at $7.5 million for Q3 2025, versus $22.5 million for Q2 2025 and $8.0 million for Q1 2025.